patients scheduled for elective PTCA who were estimated to be at moderate to high risk of sustaining ischemic complications. All patients were given aspirin and heparin. The study drug was given at least 10 minutes before PTCA. In stage 1, increasing bolus doses of c7E3 Fab were given to 15 patients; a bolus dose of 0.25 mg/kg was found to result in blockade of >80% of the receptors and reduce platelet aggregation to <20% compared with baseline, establishing this dose as that necessary to sufficiently suppress platelet activity. In stage 2, additional c7E3 Fab was administered by continuous infusion to 32 patients for progressively longer periods of time (up to 24 hours) to confirm that platelet inhibition could be maintained with prolonged drug infusion. Also, 9 patients otherwise meeting entry criteria were given placebo. There were no thrombotic events among patients receiving c7E3 Fab. Overall procedural and clinical success and complication rates as well as rates of bleeding were statistically similar among groups. However, minor bleeding was more frequent with administration of the active drug.
Conclusions
The novel antiplatelet agent c7E3 Fab can be administered during PTCA in combination with aspirin and heparin. Suppression of platelet activity is dose dependent and can be maintained for up to 24 hours. Further evaluation will be required to determine the extent of improvement in ischemic complication and restenosis rates and to provide additional insight into the safety profile of this potent monoclonal platelet antibody. (Circulation. 1994; 90:1757 -1764 Key Words * angioplasty * platelets * antibodies D espite advances in the technology of percutaneous transluminal coronary angioplasty (PTCA), this procedure remains limited by the persistent 4% to 8% incidence of abrupt closure and 28% to 56% incidence of restenosis.1-3 Uncontrolled platelet deposition has been implicated in the processes of both abrupt closure and restenosis after PTCA.4-7 Abrupt closure remains a major clinical problem and accounts for a substantial portion of the morbidity, mortality, and emergency coronary bypass surgery accompanying PTCA.1, 2 The sequence of events leading to thrombosis is initiated by the adhesion of platelets to sites of vascular injury. After adhesion, platelets become activated by local agonists, including epinephrine, ADP, collagen, serotonin, and thrombin. With activation, glycoprotein lIb/IIIa (GP 1Ib/IIIa) receptors on the platelet surface assume an active conformation. These receptors, typically numbering 50 000 to 100 000 per platelet, can then bind circulating fibrinogen, von Willebrand factor, and other adhesive proteins, resulting in platelet aggregation and ultimately thrombosis. [8] [9] [10] As originally developed, the monoclonal antibody 7E3, specific for the human platelet GP 1Ib/IIIa integrin, was entirely murine in composition. In vitro, this agent completely inhibited platelet aggregation and, in animal models of angioplasty injury and thrombolysis, prevented thrombosis and augmented the activity of thrombolytic agents.11-14 Phase 
PTCA Procedure
Patients were pretreated with aspirin (325 mg) before the PTCA procedure. Heparin was given to achieve an activated clotting time of >300 seconds or activated partial thromboplastin time of >150 seconds before balloon inflation. Either active study drug or placebo was given at least 10 minutes before balloon inflation. PTCA was otherwise performed in the usual fashion. After the procedure, heparin was continued at the discretion of the investigator. Sheaths were removed 4 to 5 hours after discontinuation of heparin and a minimum of 6 hours after the discontinuation of c7E3 Fab.
Treatment Allocation
The trial was conducted in two stages. A total of 56 patients were enrolled. The purpose of the first stage was to identify a single bolus dose of c7E3 Fab that would result in a >80% reduction in the number of available GP IIb/IIla receptor sites and a <20% platelet aggregation response to 20 gmol/L ADP at 2 hours after injection compared with baseline. Five patients each were treated with a single bolus of c7E3 Fab at 0.15, 0.20, and 0.25 mg/kg in this stage. The purpose of the second stage was to assess the effects of prolonged administration of c7E3 Fab. A total of 32 patients were given a bolus of 0.25 mg/kg c7E3 Fab immediately followed by progressively longer infusions at a rate of 10 ,ug/min. In this manner, 11 patients each were treated for 6 and 12 hours and 10 were treated for 24 hours. To complete the trial, 9 additional patients who otherwise matched entry criteria were given placebo and followed in the same fashion as patients treated with active drug.
Laboratory Studies
The effects of c7E3 Fab on platelet function were evaluated by serial measurements of platelet aggregation, GP Ilb/lIla integrin blockade, and bleeding time before and after drug administration. Three study sites obtained platelet aggregation and receptor blockade data, and all sites obtained bleeding time values. Blood was collected in 3.8% sodium citrate tubes. Platelet aggregation was determined by the turbidimetric method using 20 ,lmol/L ADP as the agonist. Assays were performed in platelet-rich plasma in either a Bio/Data PAP-4 or a Chrono-Log aggregometer. Platelet aggregation was quantified as the maximum change in light transmission occurring within 5 minutes of addition of agonist. For summary purposes, posttreatment platelet aggregation was expressed as a percentage of the individual's pretreatment aggregation. Receptor availability was calculated by the radiometric method of Coller and Scudder.21 Again, receptor availability after treatment was expressed as a percentage of the individual patient's pretreatment receptor availability. Bleeding times were determined by the Ivy template technique22 as performed by an automated incision-making instrument (Simplate II, Organon Teknika Corp). When bleeding continued beyond 30 minutes, the assay was terminated and the measurement was reported as a value truncated at 30 minutes.
Serum samples were also collected at baseline and serially after hospital discharge to assay for the development of human antichimeric antibodies. The antibody response was measured by use of a streptavidin-based enzyme immunoassay. 
Results

Baseline Patient Characteristics
Baseline characteristics are summarized in Table 1 . There were no significant differences among groups in baseline clinical or angiographic variables. All patients met entry criteria and were thus judged to be at moderate to high risk of PTCA-associated ischemic complica- Time (hours) 20 24
Tim ( The effects of administration of a 0.25 -mg/kg bolus dose of c7E3 Fab followed by a 10-,ug/min infusion for 12 hours are depicted in Fig 4. Receptor blockade, inhibition of platelet aggregation, and prolongation of bleeding time were maintained throughout the duration of the 12-hour infusion. As shown in the figure, recovery did not begin until after discontinuation of the infusion. While not illustrated, similar degrees of platelet suppression were achieved by extending the duration of infusion to Overall, there were no significant differences in clinical event rates among groups. Table 2 
Safety Profile
The safety of c7E3 Fab administration was evaluated by serial measurements of hematology and coagulation parameters, assessment of bleeding complications, and documentation of transfusion requirements. No patients developed thrombocytopenia, defined as a drop in platelet counts to <50% of baseline or absolute thrombocytopenia of 80 000 cells/,L. Mild (<20%) decreases in platelet counts were observed in all groups, including control subjects, in the first 24 hours. Similarly, all groups developed a drop in mean hemoglobin concentration, ranging from a minimum mean decrease of 1.34+1.47 g/dL in patients receiving only a bolus of 0.25 mg/kg c7E3 to a maximum mean decrease of 2.32±0.98 g/dL in patients receiving only a bolus of 0.20 mg/kg of the study drug. For all of these measures, there were no significant differences among groups, nor were dosedependent effects identified.
Of particular note is that c7E3 Fab platelet suppression could be partially reversed by the administration of fresh platelets, with recovery of normal hemostasis in two patients on transfusion of pooled random-donor platelets. A summary of bleeding events and transfusion requirements, aside from those elements attributable to coronary artery bypass surgery, is presented in Table 3 . 
Minor bleeding events, n (%) 0 4 (27) 4 (13) Major bleeding events, n (%) 0 0 3 (9) Red blood cell transfusion, n (%) Minor bleeding was in large part related to oozing and hematoma formation at the vascular access sites; three patients also developed hematuria, and five manifested minor gastrointestinal bleeding. Major bleeding occurred in three treated patients. In one patient, access site oozing was severe enough to result in a drop in hemoglobin of 6.3 g/dL (thus meeting criteria for major bleeding); this patient was managed conservatively and did not receive a blood transfusion. A second patient developed severe bleeding at an access site requiring transfusion with packed red blood cells, fresh frozen plasma, and platelets immediately before urgent coronary bypass surgery. The third patient, described previously, required multiple transfusions between 8 and 21 days postinfusion for multiple organ system failure with multiple sites of bleeding (thought not to be related to study drug administration) and was counted as meeting criteria for major bleeding.
The '28 In our population, then, this baseline rate of serious bleeding would be increased because of vascular trauma associated with access to the central circulation during catheterization. Although the incidence of bleeding complications in this study was perhaps high compared with a typical angioplasty population, these complications were largely limited to the development of clinically minor oozing and hematoma formation at vascular access sites along with a modest incidence of guaiac-positive urine and feces. However, these data also suggest that the extent of use of this agent in a particular population to prevent thrombosis will depend on the balance of thrombotic and hemorrhagic risk, with applicability outside the high-risk setting predicated on improvement of the safety profile.
The administration of potent biologics, especially those with the potential for antigenicity, poses one additional potential risk that must be considered before widespread application. Previous studies of the murine 7E3 product demonstrated the potential for antigenicity manifested by the development of low titers of IgG antibodies specific for the murine antibody.1'56 The reconstructed antibody c7E3 Fab used in this study, expressly designed to minimize antigenic potential while maintaining biological activity, was well tolerated by all patients. No adverse reactions (other than bleeding) related to administration of this agent were detected, nor did any patient develop thrombocytopenia or antibodies to the active agent. 
